EnvoyAI Made Available to Over 200 UK Healthcare Locations
LIVERPOOL, United Kingdom, June 10, 2019 (GLOBE NEWSWIRE) -- Advanced visualization and artificial intelligence (AI) technology provider, TeraRecon, today announced that it has reached agreement with Insignia Medical Systems to make its EnvoyAI™ platform available to Insignia’s vast PACS and Regional Image Sharing Platform (RISP) networks currently running in over 200 United Kingdom (U.K.) healthcare sites.
EnvoyAI is the world's first medical imaging AI marketplace and interoperability platform, currently offering over 80 algorithms with 20 holding regulatory clearances in various global territories. It allows clinicians to experiment with its ever-growing number of commercial-ready and research-use AI products. Health systems can enter into one simple contractual agreement and run all algorithms on the EnvoyAI platform identically, interchangeably, and with immediate access.
Richard Dormer, Managing Director of Insignia, said “With access to EnvoyAI via the Insignia RISP and Insignia PACS systems, we make it possible for clinicians to work locally and to collaborate with AI innovations across entire U.K. regions. Insignia client locations are home to tens of thousands of clinicians that are now able to experience EnvoyAI and access its full range of artificial intelligence algorithms alongside the impressive Insignia PACS integration and workflow capabilities.”
The U.K. National Health Service has been making significant investments in the development and adoption of AI technologies, including algorithm creation and testing of novel AI-driven medical imaging workflows. TeraRecon has also made significant investments in AI technology including the EnvoyAI platform, the Northstar™ AI Results Explorer, and a sophisticated developer portal that is used by data scientists and AI companies to turn their AI projects into secure EnvoyAI-compatible image processing engines, accessible by a rapidly growing number of EnvoyAI key opinion leaders and clinical end-user installations.
“Even the most polished and proven new algorithms cannot deliver any impact without actually being incorporated into the clinical workflow so that they can be used. We provide a revolutionary new kind of AI technology platform which allows these algorithms to be accessed and run simultaneously, and to have their remarkable results directly incorporated into the electronic health record, the radiology PACS and even clinical decision support systems” said Jeff Sorenson, President and CEO of TeraRecon. He continued, “This partnership is one of the first of its kind to extend the reach of imaging AI far beyond the academic or research realm into the regional and community facilities that arguably need it most.”
TeraRecon technologies including the EnvoyAI platform, TeraRecon Northstar AI Results Explorer, and its flagship iNtuition™ advanced visualization solution, will be on display at the UK Imaging and Oncology Congress (Book a demo at UKIO) in Liverpool, England from June 10th – June 12th, 2019. Online demonstrations are available by contacting TeraRecon at email@example.com.
About TeraRecon (www.terarecon.com) TeraRecon is a leader in medical advanced visualization and artificial intelligence solutions. Our flagship product, iNtuition, consistently leads the advanced visualization category of the industry’s leading independent technology analyst. The company continues to innovate ahead of customer demand and has most recently developed new sophisticated healthcare-focused artificial intelligence platform solutions unlike any in the world today. EnvoyAI was the recipient of the prestigious Aunt Minnie 2018 Best New Radiology Vendor award. TeraRecon’s Northstar AI Results Explorer is the first and only enterprise-wide solution capable of delivering AI imaging insights directly and interactively into the systems clinicians use every day. As a company with a 20-year history of innovation, TeraRecon’s mission is to continuously redefine medical advanced visualization and leverage artificial intelligence to improve patient care.
About Insignia (www.insigniamedical.co.uk) Insignia Medical Systems is the pioneering UK-based medical imaging provider offering technology-leading solutions. With over 18 years pedigree, Insignia has unrivalled experience in providing services that help improve the delivery of healthcare and outcomes for patients.
Press Inquiries US: 1-650-372-1100 | firstname.lastname@example.org
TeraRecon, iNtuition, EnvoyAI, and Northstar are trademarks of TeraRecon, Inc.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
AIR Collaborates with Precisely to Offer Clients Premium International Geocoding in Touchstone 202015.7.2020 12:13:10 CEST | Press release
Boston, July 15, 2020 (GLOBE NEWSWIRE) -- Catastrophe modeling firm AIR Worldwide today announced that as part of its Touchstone® 2020 software release, clients now have the ability to access a premium international address-level geocoding feature from Precisely, the global leader in data integrity, to enhance the quality of their exposure data. AIR Worldwide is a Verisk (Nasdaq:VRSK) business. “Using high quality exposure data, such as any information about the property, its replacement value, and its physical characteristics including the location of that property, has a significant impact on the loss results generated by a catastrophe model,” said Gayatri Natarajan, vice president of product, AIR Worldwide. “Having the right latitude and longitude coordinates for a property can have an enormous bearing upon the accuracy of risk estimation and the impact that extreme events might have on that property. Through our collaboration with Precisely, Touchstone 2020 will help support client
Medtronic to Acquire Medicrea15.7.2020 08:30:10 CEST | Press release
Medtronic Will Become the First Company to Offer an Integrated Solution Including Artificial Intelligence-Driven Surgical Planning, Personalized Spinal Implants and Robotic Assisted Surgery DUBLIN and LYON, France, July 15, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), a global leader in medical technology, and Medicrea (Euronext Growth Paris: FR0004178572 – ALMED Medicrea; OTCQX Best Market – MRNTF), a pioneer in the transformation of spinal surgery through artificial intelligence, predictive modeling and patient specific implants, today announced that they have entered into a tender offer agreement for the acquisition of all outstanding shares of Medicrea. The friendly voluntary all-cash tender offer will be at a price of €7.00 per Medicrea share (the “Tender Offer”). The Boards of Directors of both companies have unanimously approved the transaction. This acquisition would strengthen Medtronic’s position as a global innovator in enabling technologies and solutions for spine sur
Program for the publication of Yara International ASA second quarter results 202015.7.2020 08:00:00 CEST | Press release
The Yara International ASA second quarter 2020 report and presentation will be published on Friday 17 July 2020at08:00 CEST. An on-line presentation and Q&A session will be held at 12:00 CEST, hosted by Yara President and CEO Svein Tore Holsether, CFO Lars Røsæg, EVP Global Plants & Operational Excellence Pål Hestad and EVP Farming Solutions Terje Knutsen. The presentation will be held in English. The report, presentation and webcast will be available at the above mentioned times at: yara.com/investor-relations/latest-quarterly-report/ Yours faithfully for Yara International ASA Thor Giæver Head of Investor Relations About Yara Yara grows knowledge to responsibly feed the world and protect the planet. Supporting our vision of a world without hunger, we pursue a strategy of sustainable value growth, promoting climate-friendly and high-yielding crop nutrition solutions for the world’s farming community and food industry. Yara’s ambition is to be the Crop Nutrition Company for the Future.
Program for offentliggjøring av Yara International ASA 2. kvartalsrapport 202015.7.2020 08:00:00 CEST | Pressemelding
Yara International ASAs resultatrapport og presentasjon for 2. kvartal 2020 offentliggjøres fredag 17. juli 2020kl. 08.00. Det vil holdes en nettbasert presentasjon og Q&A kl. 12.00. Resultatene vil presenteres av konsernsjef Svein Tore Holsether, finansdirektør Lars Røsæg, konserndirektør for Global plants & Operational Excellence Pål Hestad og konserndirektør for Farming Solutions Terje Knutsen. Presentasjonen vil bli holdt på engelsk. Resultatrapport, presentasjon og webcast vil være tilgjengelige til ovennevnte tider på: yara.com/investor-relations/latest-quarterly-report/ Med hilsen for Yara International ASA Thor Giæver Investorkontakt Om Yara Yara bringer kunnskap om hvordan verdens befolkning kan mettes og kloden beskyttes. Bak vår visjon om en verden uten sult ligger en strategi som fremmer klimavennlige og ressurseffektive løsninger for landbruk og matvareindustri over hele verden. Vår ambisjon er å være fremtidens leverandør av plantenæring. Vi har forpliktet oss til å skape
Interim report 2020, January - June15.7.2020 08:00:00 CEST | Press release
Second quarter Net sales for the second quarter reached SEK 355 m (416), corresponding to a decrease of 15%. Currency translations had a negative effect of SEK 2 m on net salesOrder intake was SEK 302 m (375), corresponding to a decrease of 19%Operating profit reached SEK 69 m (72) equal to a 19.4% (17.3) operating marginProfit after taxes totalled SEK 54 m (51) and earnings per share was SEK 1.24 (1.10)Cash flow from operating activities amounted to SEK 115 m (51) First six months Net sales for the first six months reached SEK 716 m (796), corresponding to a 10% decrease. Currency translations had a positive effect of SEK 1 m on net salesOrder intake was SEK 703 m (762), corresponding to a decrease of 8%Operating profit was SEK 136 m (132), equal to a 18.9% (16.6) operating marginProfit after taxes totalled SEK 102 m (92) and the earnings per share was SEK 2.26 (1.98)Cash flow from operating activities amounted to SEK 170 m (103) Comment from the CEO The second quarter of the year was
Quarterly Report January – June 202015.7.2020 08:00:00 CEST | Press release
First six months 2020 Net sales amounted to MSEK 5,386 (5,525), which was an organic decrease by five percentage points compared to the same period last year. Adjusted EBITA amounted to MSEK 153 (235), which corresponded to an adjusted EBITA margin of 2.8 (4.2) percent. Operating cash flow amounted to MSEK 635 (641), of which acquisitions and divestitures of operations were MSEK 0 (-5). Second quarter 2020 Net sales increased to MSEK 2,814 (2,719), which was an organic increase by two percentage points, compared to the same period last year. Adjusted EBITA amounted to MSEK 72 (122), which corresponded to an adjusted EBITA margin of 2.6 (4.5) percent. The COVID-19 pandemic had a significant negative effect on the European operations. One-off business relating to procurement of personal protective equipment helped the Group’s Asian operations to perform better than last year.Liquidity measures and strict cost control have made it possible to protect the Group’s liquidity buffer. Existing